目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key secondary sources
2.1.1.2 Key data from secondary sources
2.1.1.3 Objectives of secondary research
2.1.2 PRIMARY DATA
2.1.2.1 Key primary sources
2.1.2.2 Key data from primary sources
2.1.2.3 Key industry insights
2.1.2.4 Breakdown of primaries
2.1.2.4.1 Breakdown of primary interviews: supply & demand-side
2.1.2.4.2 Breakdown of primary interviews: by company type, designation, and region
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.1.1 Company revenue estimation approach
2.2.1.2 Presentations of companies and primary interviews
2.2.1.3 Growth forecast
2.2.1.4 CAGR projections
2.2.2 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 MARKET SHARE ANALYSIS
2.5 ASSUMPTIONS
2.5.1 STUDY ASSUMPTIONS
2.5.2 GROWTH RATE ASSUMPTIONS
2.6 LIMITATIONS
2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 LATENT TB TESTING MARKET OVERVIEW
4.2 LATENT TB TESTING MARKET, BY TEST TYPE, 2024 VS. 2029
4.3 LATENT TB TESTING MARKET, BY APPLICATION, 2024 VS. 2029
4.4 LATENT TB TESTING MARKET, BY END USER, 2024 VS. 2029
4.5 LATENT TB TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Rising incidence of latent tuberculosis
5.2.1.2 Widespread use of BCG vaccine
5.2.1.3 Increased funding and grants for TB control programs
5.2.2 RESTRAINTS
5.2.2.1 Unfavorable reimbursement scenario
5.2.3 OPPORTUNITIES
5.2.3.1 Growth opportunities in emerging economies
5.2.4 CHALLENGES
5.2.4.1 Changing regulatory landscape
5.2.4.2 Operational barriers and labor shortage
5.3 PRICING ANALYSIS
5.3.1 AVERAGE SELLING PRICE, BY PRODUCT
5.3.2 INDICATIVE PRICE OF IGRA TESTS, BY REGION
5.4 PATENT ANALYSIS
5.4.1 LIST OF MAJOR PATENTS
5.5 VALUE CHAIN ANALYSIS
5.6 SUPPLY CHAIN ANALYSIS
5.7 TRADE ANALYSIS
5.7.1 IMPORT DATA
5.7.2 EXPORT DATA
5.8 ECOSYSTEM ANALYSIS
5.8.1 ROLE IN ECOSYSTEM
5.9 PORTER'S FIVE FORCES ANALYSIS
5.9.1 THREAT OF NEW ENTRANTS
5.9.2 THREAT OF SUBSTITUTES
5.9.3 BARGAINING POWER OF BUYERS
5.9.4 BARGAINING POWER OF SUPPLIERS
5.9.5 INTENSITY OF COMPETITIVE RIVALRY
5.10 KEY STAKEHOLDERS AND BUYING CRITERIA
5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.10.2 KEY BUYING CRITERIA
5.11 REGULATORY ANALYSIS
5.11.1 REGULATORY LANDSCAPE
5.11.1.1 North America
5.11.1.1.1 US
5.11.1.1.2 Canada
5.11.1.2 Europe
5.11.1.2.1 Germany
5.11.1.2.2 UK
5.11.1.2.3 France
5.11.1.2.4 Italy
5.11.1.2.5 Spain
5.11.1.3 Asia Pacific
5.11.1.3.1 China
5.11.1.3.2 Japan
5.11.1.3.3 India
5.11.1.3.4 Australia
5.11.1.3.5 South Korea
5.11.1.3.6 Singapore
5.11.1.4 Latin America
5.11.1.4.1 Brazil
5.11.1.4.2 Mexico
5.11.1.5 Middle East
5.11.1.5.1 Africa
5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.11.2.1 North America
5.11.2.2 Europe
5.11.2.3 Asia Pacific
5.11.2.4 Latin America
5.11.2.5 Rest of the world
5.12 TECHNOLOGY ANALYSIS
5.12.1 KEY TECHNOLOGIES
5.12.1.1 Tuberculin skin test
5.12.2 COMPLEMENTARY TECHNOLOGIES
5.12.2.1 Interferon gamma released assay
5.13 KEY CONFERENCES AND EVENTS, 2024-2025
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.15 INVESTMENT & FUNDING SCENARIO
5.16 CASE STUDY ANALYSIS
5.16.1 CASE STUDY 1: EXPLORING CYTOKINE USAGE IN MONITORING LTBI TREATMENT
5.16.2 CASE STUDY 2: ASSESSING DIAGNOSTIC ACCURACY OF ESAT6-CFP10 (EC) SKIN TEST FOR LTBI DETECTION
5.16.3 CASE STUDY 3: EVALUATING MTB-SPECIFIC CYTOKINE RESPONSES FOR ENHANCED LTBI DETECTION IN HEU INFANTS
5.17 LATENT TB CONTROL STRATEGIES IN MAJOR COUNTRIES
5.17.1 NORTH AMERICA
5.17.1.1 US
5.17.1.2 Canada
5.17.2 EUROPE
5.17.2.1 Germany
5.17.2.2 UK
5.17.3 ASIA PACIFIC
5.17.3.1 Japan
5.17.3.2 China
5.17.3.3 India
5.17.3.4 Singapore
5.18 IMPACT OF AI ON LATENT TB TESTING MARKET
5.18.1 KEY USE CASES

6 LATENT TB TESTING MARKET, BY TEST TYPE
6.1 INTRODUCTION
6.2 IGRA
6.2.1 HIGHER SPECIFICITY AND ACCURACY TO BOOST MARKET SEGMENT
6.3 TST
6.3.1 COST-EFFECTIVENESS TO PROPEL MARKET GROWTH

7 LATENT TB TESTING MARKET, BY APPLICATION
7.1 INTRODUCTION
7.2 PEOPLE LIVING WITH HIV
7.2.1 RISING RATES OF TB-HIV COINFECTION TO PROPEL GROWTH
7.3 HOUSEHOLD CONTACTS (HHC) WITH PULMONARY TUBERCULOSIS (TB)/ HOUSEHOLD CONTACTS (HHC) OF TUBERCULOSIS (TB) PATIENTS
7.3.1 NEED FOR ROUTINE SCREENING FOR HOUSEHOLD CONTACTS TO BOOST SEGMENT
7.4 OTHER APPLICATIONS

8 LATENT TB TESTING MARKET, BY END USER
8.1 INTRODUCTION
8.2 DIAGNOSTIC LABORATORIES
8.2.1 WELL-DEVELOPED INFRASTRUCTURE AND CAPABILITIES TO SUPPORT DEMAND FOR TESTING METHODS
8.3 HOSPITALS & CLINICS
8.3.1 GROWING NUMBER OF HOSPITALS AND GOVERNMENT INVESTMENTS IN HEALTHCARE TO BOOST SEGMENT
8.4 ACADEMIC & RESEARCH INSTITUTES
8.4.1 RISING INDUSTRY-ACADEMIA COLLABORATIONS TO SUPPORT MARKET GROWTH
8.5 OTHER END USERS

9 LATENT TB TESTING MARKET, BY REGION
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
9.2.2 US
9.2.2.1 US to dominate North American latent TB testing market
9.2.3 CANADA
9.2.3.1 Improved screening and treatment for latent TB to drive market
9.3 ASIA PACIFIC
9.3.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
9.3.2 CHINA
9.3.2.1 Growing public access to modern healthcare to fuel market growth
9.3.3 JAPAN
9.3.3.1 Presence of universal healthcare reimbursement policy to drive market
9.3.4 INDIA
9.3.4.1 High TB burden and growing government initiatives to drive demand for latent TB screening
9.3.5 SOUTH KOREA
9.3.5.1 Rising healthcare spending in innovative diagnostic technologies to support market growth
9.3.6 AUSTRALIA
9.3.6.1 Diverse immigrant population to fuel demand for latent TB screening
9.3.7 SINGAPORE
9.3.7.1 Enhanced healthcare infrastructure to propel market growth
9.3.8 REST OF ASIA PACIFIC
9.4 EUROPE
9.4.1 EUROPE: MACROECONOMIC OUTLOOK
9.4.2 UK
9.4.2.1 Growing number of diagnostic centers to fuel market
9.4.3 FRANCE
9.4.3.1 Presence of robust healthcare system to augment market growth
9.4.4 GERMANY
9.4.4.1 Higher healthcare spending and favorable government policies to favor market growth
9.4.5 SPAIN
9.4.5.1 Improving healthcare infrastructure to drive demand
9.4.6 ITALY
9.4.6.1 Improved quality of medical care to spur market growth
9.4.7 BELGIUM
9.4.7.1 Targeted screening for high-risk groups to fuel demand
9.4.8 SWEDEN
9.4.8.1 Growing immigrant population from high-prevalence regions to propel demand
9.4.9 DENMARK
9.4.9.1 Importance of latent TB testing in public health strategy to support market growth
9.4.10 REST OF EUROPE
9.5 LATIN AMERICA
9.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
9.5.2 BRAZIL
9.5.2.1 Developed public health systems and improving healthcare infrastructure to favor market growth
9.5.3 MEXICO
9.5.3.1 Modernization of healthcare infrastructure to augment market growth
9.5.4 REST OF LATIN AMERICA
9.6 MIDDLE EAST & AFRICA
9.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
9.6.2 SOUTH AFRICA
9.6.2.1 Rising government initiatives for TB screening to augment market growth
9.6.3 SAUDI ARABIA
9.6.3.1 Enhancements in healthcare infrastructure to support market growth
9.6.4 UAE
9.6.4.1 UAE ranks among the world's leading countries with low TB rates
9.6.5 KUWAIT
9.6.5.1 Expansion of healthcare infrastructure to augment market growth
9.6.6 REST OF MIDDLE EAST & AFRICA

10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN LATENT TB TESTING MARKET
10.3 REVENUE SHARE ANALYSIS
10.4 MARKET SHARE ANALYSIS
10.4.1 MARKET SHARE ANALYSIS, BY REGION
10.4.1.1 North America
10.4.1.2 Europe
10.4.1.3 Asia Pacific
10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
10.5.1 STARS
10.5.2 EMERGING LEADERS
10.5.3 PERVASIVE PLAYERS
10.5.4 PARTICIPANTS
10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
10.5.5.1 Company footprint
10.5.5.2 Test type footprint
10.5.5.3 Application footprint
10.5.5.4 Region footprint
10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
10.6.1 PROGRESSIVE COMPANIES
10.6.2 RESPONSIVE COMPANIES
10.6.3 DYNAMIC COMPANIES
10.6.4 STARTING BLOCKS
10.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
10.7.1 COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS, 2023
10.8 VALUATION & FINANCIAL METRICS
10.9 BRAND/PRODUCT COMPARATIVE ANALYSIS
10.9.1 QIAGEN
10.9.2 REVVITY
10.9.3 BIOMERIEUX
10.10 COMPETITIVE SCENARIO
10.10.1 PRODUCT LAUNCHES
10.10.2 DEALS

11 COMPANY PROFILES
11.1 KEY PLAYERS
11.1.1 QIAGEN
11.1.1.1 Business overview
11.1.1.2 Products offered
11.1.1.3 Recent developments
11.1.1.3.1 Product launches & approvals
11.1.1.3.2 Deals
11.1.1.3.3 Expansions
11.1.1.4 MnM view
11.1.1.4.1 Right to win
11.1.1.4.2 Strategic choices
11.1.1.4.3 Weaknesses & competitive threats
11.1.2 REVVITY (OXFORD IMMUNOTEC)
11.1.2.1 Business overview
11.1.2.2 Products offered
11.1.2.3 Recent developments
11.1.2.3.1 Product launches & approvals
11.1.2.4 MnM view
11.1.2.4.1 Right to win
11.1.2.4.2 Strategic choices
11.1.2.4.3 Weaknesses & competitive threats
11.1.3 BEIJING WANTAI BIOPHARMACEUTICAL CO., LTD.
11.1.3.1 Business overview
11.1.3.2 Products offered
11.1.3.3 MnM view
11.1.3.3.1 Right to win
11.1.3.3.2 Strategic choices
11.1.3.3.3 Weaknesses & competitive threats
11.1.4 SANOFI
11.1.4.1 Business overview
11.1.4.2 MnM view
11.1.4.2.1 Right to win
11.1.4.2.2 Strategic choices
11.1.4.2.3 Weaknesses & competitive threats
11.1.5 ENDO, INC.
11.1.5.1 Business overview
11.1.5.2 Products offered
11.1.5.3 MnM view
11.1.5.3.1 Key strengths
11.1.5.3.2 Strategic choices
11.1.5.3.3 Weaknesses and competitive threats
11.1.6 BIOMERIEUX
11.1.6.1 Business overview
11.1.6.2 Products offered
11.1.6.3 Recent developments
11.1.6.3.1 Product approvals
11.1.7 SD BIOSENSOR, INC.
11.1.7.1 Business overview
11.1.7.2 Products offered
11.1.7.3 Recent developments
11.1.7.3.1 Deals
11.1.8 LIONEX GMBH
11.1.8.1 Business overview
11.1.8.2 Products offered
11.1.9 SERUM INSTITUTE OF INDIA PVT. LTD.
11.1.9.1 Business overview
11.1.9.2 Products offered
11.1.10 ARKRAY, INC.
11.1.10.1 Business overview
11.1.10.2 Products offered
11.1.10.3 Recent developments
11.1.10.3.1 Expansions
11.2 OTHER PLAYERS
11.2.1 ZHI FEI BIOLOGICAL
11.2.2 AID AUTOIMMUN DIAGNOSTIKA GMBH
11.2.3 BODITECH MED INC.
11.2.4 BIONEOVAN CO., LTD.
11.2.5 BIOPANDA REAGENTS LTD.

12 APPENDIX
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
12.3 CUSTOMIZATION OPTIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS

List of Tables
TABLE 1 LATENT TB TESTING MARKET: RISK ASSESSMENT
TABLE 2 COMMERCIALLY AVAILABLE IGRA TESTS, BY KEY PLAYER
TABLE 3 AVERAGE SELLING PRICE OF LATENT TB TESTS, 2022-2024
TABLE 4 INDICATIVE PRICE OF IGRA TESTS, BY REGION, 2022-2024
TABLE 5 LATENT TB TESTING MARKET: LIST OF MAJOR PATENTS, 2022-2023
TABLE 6 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2019-2023 (USD MILLION)
TABLE 7 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2019-2023 (USD MILLION)
TABLE 8 LATENT TB TESTING MARKET: ROLE IN ECOSYSTEM
TABLE 9 LATENT TB TESTING MARKET: PORTER'S FIVE FORCES ANALYSIS
TABLE 10 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF LATENT TB TESTS (%)
TABLE 11 KEY BUYING CRITERIA FOR LATENT TB TESTS, BY TYPE
TABLE 12 CLASSIFICATION OF DEVICES IN EUROPE
TABLE 13 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
TABLE 14 AUSTRALIA: CLASSIFICATION OF IVD MEDICAL DEVICES
TABLE 15 NORTH AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 16 EUROPE: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 17 ASIA PACIFIC: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 18 LATIN AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 19 REST OF THE WORLD: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 20 LATENT TB TESTING MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS
TABLE 21 LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 22 LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS)
TABLE 23 BCG VACCINATION COVERAGE, BY REGION, 2021 VS 2022 VS 2023 (%)
TABLE 24 COMMERCIALLY AVAILABLE IGRA PRODUCTS, BY COMPANY
TABLE 25 LATENT TB TESTING MARKET FOR IGRA, BY REGION, 2022-2029 (USD MILLION)
TABLE 26 NORTH AMERICA: LATENT TB TESTING MARKET FOR IGRA, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 27 EUROPE: LATENT TB TESTING MARKET FOR IGRA, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 28 ASIA PACIFIC: LATENT TB TESTING MARKET FOR IGRA, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 29 LATIN AMERICA: LATENT TB TESTING MARKET FOR IGRA, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 30 MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET FOR IGRA, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 31 COMMERCIALLY AVAILABLE TST PRODUCTS IN MARKET, BY COMPANY
TABLE 32 LATENT TB TESTING MARKET FOR TST, BY REGION, 2022-2029 (USD MILLION)
TABLE 33 NORTH AMERICA: LATENT TB TESTING MARKET FOR TST, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 34 EUROPE: LATENT TB TESTING MARKET FOR TST, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 35 ASIA PACIFIC: LATENT TB TESTING MARKET FOR TST, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 36 LATIN AMERICA: LATENT TB TESTING MARKET FOR TST, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 37 MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET FOR TST, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 38 LATENT TB TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 39 LATENT TB TESTING MARKET FOR PEOPLE LIVING WITH HIV, BY REGION, 2022-2029 (USD MILLION)
TABLE 40 NORTH AMERICA: LATENT TB TESTING MARKET FOR PEOPLE LIVING WITH HIV, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 41 EUROPE: LATENT TB TESTING MARKET FOR PEOPLE LIVING WITH HIV, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 42 ASIA PACIFIC: LATENT TB TESTING MARKET FOR PEOPLE LIVING WITH HIV, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 43 LATIN AMERICA: LATENT TB TESTING MARKET FOR PEOPLE LIVING WITH HIV, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 44 MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET FOR PEOPLE LIVING WITH HIV, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 45 LATENT TB TESTING MARKET FOR HOUSEHOLD CONTACTS WITH PULMONARY TB, BY REGION, 2022-2029 (USD MILLION)
TABLE 46 NORTH AMERICA: LATENT TB TESTING MARKET FOR HOUSEHOLD CONTACTS WITH PULMONARY TB, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 47 EUROPE: LATENT TB TESTING MARKET FOR HOUSEHOLD CONTACTS WITH PULMONARY TB, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 48 ASIA PACIFIC: LATENT TB TESTING MARKET FOR HOUSEHOLD CONTACTS WITH PULMONARY TB, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 49 LATIN AMERICA: LATENT TB TESTING MARKET FOR HOUSEHOLD CONTACTS WITH PULMONARY TB, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 50 MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET FOR HOUSEHOLD CONTACTS WITH PULMONARY TB, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 51 LATENT TB TESTING MARKET FOR OTHER APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
TABLE 52 NORTH AMERICA: LATENT TB TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 53 EUROPE: LATENT TB TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 54 ASIA PACIFIC: LATENT TB TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 55 LATIN AMERICA: LATENT TB TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 56 MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 57 LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 58 LATENT TB TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2022-2029 (USD MILLION)
TABLE 59 NORTH AMERICA: LATENT TB TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 60 EUROPE: LATENT TB TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 61 ASIA PACIFIC: LATENT TB TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 62 LATIN AMERICA: LATENT TB TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 63 MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 64 US: NUMBER OF COMMUNITY HOSPITALS, 2020 -VS 2021
TABLE 65 LATENT TB TESTING MARKET FOR HOSPITALS & CLINICS, BY REGION, 2022-2029 (USD MILLION)
TABLE 66 NORTH AMERICA: LATENT TB TESTING MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 67 EUROPE: LATENT TB TESTING MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 68 ASIA PACIFIC: LATENT TB TESTING MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 69 LATIN AMERICA: LATENT TB TESTING MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 70 MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 71 LATENT TB TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2022-2029 (USD MILLION)
TABLE 72 NORTH AMERICA: LATENT TB TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 73 EUROPE: LATENT TB TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 74 ASIA PACIFIC: LATENT TB TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 75 LATIN AMERICA: LATENT TB TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 76 MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 77 LATENT TB TESTING MARKET FOR OTHER END USERS, BY REGION, 2022-2029 (USD MILLION)
TABLE 78 NORTH AMERICA: LATENT TB TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 79 EUROPE: LATENT TB TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 80 ASIA PACIFIC: LATENT TB TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 81 LATIN AMERICA: LATENT TB TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 82 MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 83 LATENT TB TESTING MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 84 NORTH AMERICA: MACROINDICATORS FOR LATENT TB TESTING MARKET
TABLE 85 NORTH AMERICA: LATENT TB TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 86 NORTH AMERICA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 87 NORTH AMERICA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS)
TABLE 88 NORTH AMERICA: LATENT TB TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 89 NORTH AMERICA: LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 90 US: MAIN TB/LTBI INSTITUTIONS
TABLE 91 US: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 92 US: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS)
TABLE 93 US: LATENT TB TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 94 US: LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 95 CANADA: MAIN TB/LTBI INSTITUTIONS
TABLE 96 CANADA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 97 CANADA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS)
TABLE 98 CANADA: LATENT TB TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 99 CANADA: LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 100 ASIA PACIFIC: MACROECONOMIC INDICATORS FOR LATENT TB TESTING MARKET
TABLE 101 ASIA PACIFIC: LATENT TB TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 102 ASIA PACIFIC: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 103 ASIA PACIFIC: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS)
TABLE 104 ASIA PACIFIC: LATENT TB TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 105 ASIA PACIFIC: LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 106 CHINA: MAIN TB/LTBI INSTITUTIONS
TABLE 107 CHINA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 108 CHINA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS)
TABLE 109 CHINA: LATENT TB TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 110 CHINA: LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 111 JAPAN: MAIN TB/LTBI INSTITUTIONS
TABLE 112 JAPAN: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 113 JAPAN: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS)
TABLE 114 JAPAN: LATENT TB TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 115 JAPAN: LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 116 INDIA: MAIN TB/LTBI INSTITUTIONS
TABLE 117 INDIA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 118 INDIA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS)
TABLE 119 INDIA: LATENT TB TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 120 INDIA: LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 121 SOUTH KOREA: MAIN TB/LTBI INSTITUTIONS
TABLE 122 SOUTH KOREA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 123 SOUTH KOREA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS)
TABLE 124 SOUTH KOREA: LATENT TB TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 125 SOUTH KOREA: LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 126 AUSTRALIA: MAIN TB/LTBI INSTITUTIONS
TABLE 127 AUSTRALIA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 128 AUSTRALIA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS)
TABLE 129 AUSTRALIA: LATENT TB TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 130 AUSTRALIA: LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 131 SINGAPORE: MAIN TB/LTBI INSTITUTIONS
TABLE 132 SINGAPORE: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 133 SINGAPORE: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS)
TABLE 134 SINGAPORE: LATENT TB TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 135 SINGAPORE: LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 136 REST OF ASIA PACIFIC: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 137 REST OF ASIA PACIFIC: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS)
TABLE 138 REST OF ASIA PACIFIC: LATENT TB TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 139 REST OF ASIA PACIFIC: LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 140 EUROPE: MACROINDICATORS FOR LATENT TB TESTING MARKET
TABLE 141 EUROPE: LATENT TB TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 142 EUROPE: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 143 EUROPE: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS)
TABLE 144 EUROPE: LATENT TB TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 145 EUROPE: LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 146 UK: MAIN TB/LTBI INSTITUTIONS
TABLE 147 UK: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 148 UK: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS)
TABLE 149 UK: LATENT TB TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 150 UK: LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 151 FRANCE: MAIN TB/LTBI INSTITUTIONS
TABLE 152 FRANCE: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 153 FRANCE: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS)
TABLE 154 FRANCE: LATENT TB TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 155 FRANCE: LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 156 GERMANY: MAIN TB/LTBI INSTITUTIONS
TABLE 157 GERMANY: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 158 GERMANY: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS)
TABLE 159 GERMANY: LATENT TB TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 160 GERMANY: LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 161 SPAIN: MAIN TB/LTBI INSTITUTIONS
TABLE 162 SPAIN: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 163 SPAIN: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS)
TABLE 164 SPAIN: LATENT TB TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 165 SPAIN: LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 166 ITALY: MAIN TB/LTBI INSTITUTIONS
TABLE 167 ITALY: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 168 ITALY: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS)
TABLE 169 ITALY: LATENT TB TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 170 ITALY: LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 171 BELGIUM: MAIN TB/LTBI INSTITUTIONS
TABLE 172 BELGIUM: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 173 BELGIUM: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS)
TABLE 174 BELGIUM: LATENT TB TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 175 BELGIUM: LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 176 SWEDEN: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 177 SWEDEN: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS)
TABLE 178 SWEDEN: LATENT TB TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 179 SWEDEN: LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 180 DENMARK: MAIN TB/LTBI INSTITUTIONS
TABLE 181 DENMARK: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 182 DENMARK: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS)
TABLE 183 DENMARK: LATENT TB TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 184 DENMARK: LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 185 REST OF EUROPE: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 186 REST OF EUROPE: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS)
TABLE 187 REST OF EUROPE: LATENT TB TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 188 REST OF EUROPE: LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 189 LATIN AMERICA: MACROINDICATORS FOR LATENT TB TESTING MARKET
TABLE 190 LATIN AMERICA: LATENT TB TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 191 LATIN AMERICA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 192 LATIN AMERICA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS)
TABLE 193 LATIN AMERICA: LATENT TB TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 194 LATIN AMERICA: LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 195 BRAZIL: MAIN TB/LTBI INSTITUTIONS
TABLE 196 BRAZIL: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 197 BRAZIL: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS)
TABLE 198 BRAZIL: LATENT TB TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 199 BRAZIL: LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 200 MEXICO: MAIN TB/LTBI INSTITUTIONS
TABLE 201 MEXICO: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 202 MEXICO: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS)
TABLE 203 MEXICO: LATENT TB TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 204 MEXICO: LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 205 REST OF LATIN AMERICA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 206 REST OF LATIN AMERICA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS)
TABLE 207 REST OF LATIN AMERICA: LATENT TB TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 208 REST OF LATIN AMERICA: LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 209 MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 210 MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 211 MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS)
TABLE 212 MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 213 MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 214 SOUTH AFRICA: MAIN TB/LTBI INSTITUTIONS
TABLE 215 SOUTH AFRICA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 216 SOUTH AFRICA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS)
TABLE 217 SOUTH AFRICA: LATENT TB TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 218 SOUTH AFRICA: LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 219 SAUDI ARABIA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 220 SAUDI ARABIA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS)
TABLE 221 SAUDI ARABIA: LATENT TB TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 222 SAUDI ARABIA: LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 223 UAE: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 224 UAE: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS)
TABLE 225 UAE: LATENT TB TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 226 UAE: LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 227 KUWAIT: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 228 KUWAIT: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS)
TABLE 229 KUWAIT: LATENT TB TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 230 KUWAIT: LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 231 REST OF MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 232 REST OF MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022-2029 (IN MILLIONS)
TABLE 233 REST OF MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 234 REST OF MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 235 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MANUFACTURING COMPANIES
TABLE 236 LATENT TB TESTING MARKET: DEGREE OF COMPETITION
TABLE 237 LATENT TB TESTING MARKET: TEST TYPE FOOTPRINT
TABLE 238 LATENT TB TESTING MARKET: APPLICATION FOOTPRINT
TABLE 239 LATENT TB TESTING MARKET: REGION FOOTPRINT
TABLE 240 LATENT TB TESTING MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS
TABLE 241 LATENT TB TESTING MARKET: COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS
TABLE 242 LATENT TB TESTING MARKET: PRODUCT LAUNCHES, JANUARY 2021-SEPTEMBER 2024
TABLE 243 LATENT TB TESTING MARKET: DEALS, JANUARY 2021-SEPTEMBER 2024
TABLE 244 QIAGEN: COMPANY OVERVIEW
TABLE 245 QIAGEN: PRODUCTS OFFERED
TABLE 246 QIAGEN: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-SEPTEMBER 2024
TABLE 247 QIAGEN: DEALS, JANUARY 2021-SEPTEMBER 2024
TABLE 248 QIAGEN: EXPANSIONS, JANUARY 2021-SEPTEMBER 2024
TABLE 249 REVVITY: COMPANY OVERVIEW
TABLE 250 REVVITY: PRODUCTS OFFERED
TABLE 251 REVVITY: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-SEPTEMBER 2024
TABLE 252 BEIJING WANTAI BIOPHARMACEUTICAL: COMPANY OVERVIEW
TABLE 253 BEIJING WANTAI BIOPHARMACEUTICAL: PRODUCTS OFFERED
TABLE 254 SANOFI: COMPANY OVERVIEW
TABLE 255 SANOFI: PRODUCTS OFFERED
TABLE 256 ENDO: COMPANY OVERVIEW
TABLE 257 ENDO: PRODUCTS OFFERED
TABLE 258 BIOMERIEUX: COMPANY OVERVIEW
TABLE 259 BIOMERIEUX: PRODUCTS OFFERED
TABLE 260 BIOMERIEUX: PRODUCT APPROVALS, JANUARY 2021-SEPTEMBER 2024
TABLE 261 SD BIOSENSOR: COMPANY OVERVIEW
TABLE 262 SD BIOSENSOR: PRODUCTS OFFERED
TABLE 263 SD BIOSENSOR: DEALS, JANUARY 2021-SEPTEMBER 2024
TABLE 264 LIONEX GMBH: COMPANY OVERVIEW
TABLE 265 LIONEX GMBH: PRODUCTS OFFERED
TABLE 266 SERUM INSTITUTE OF INDIA: COMPANY OVERVIEW
TABLE 267 SERUM INSTITUTE OF INDIA: PRODUCTS OFFERED
TABLE 268 ARKRAY: COMPANY OVERVIEW
TABLE 269 ARKRAY: PRODUCTS OFFERED
TABLE 270 ARKRAY: EXPANSIONS, JANUARY 2021-SEPTEMBER 2024

List of Figures
FIGURE 1 LATENT TB TESTING MARKET: RESEARCH DESIGN
FIGURE 2 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
FIGURE 3 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 4 LATENT TB TESTING MARKET: TOP-DOWN APPROACH
FIGURE 5 LATENT TB TESTING MARKET: DATA TRIANGULATION
FIGURE 6 LATENT TB TESTING MARKET: STUDY ASSUMPTIONS
FIGURE 7 LATENT TB TESTING MARKET, BY TEST TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 8 LATENT TB TESTING MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
FIGURE 9 LATENT TB TESTING MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
FIGURE 10 LATENT TB TESTING MARKET, BY REGION, 2024 VS. 2029 (USD MILLION)
FIGURE 11 INCREASING PREVALENCE OF LATENT TB AND GROWING FINANCIAL SUPPORT FOR TB CONTROL TO DRIVE MARKET
FIGURE 12 IGRA WILL CONTINUE TO DOMINATE MARKET TILL 2029
FIGURE 13 PEOPLE LIVING WITH HIV SEGMENT TO HOLD LARGEST MARKET SHARE
FIGURE 14 DIAGNOSTIC LABORATORIES SEGMENT TO RETAIN DOMINANT MARKET SHARE TILL 2029
FIGURE 15 ASIA PACIFIC TO REGISTER HIGHEST GROWTH
FIGURE 16 LATENT TB TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 17 PATENT ANALYSIS FOR LATENT TB TESTS (JANUARY 2014-DECEMBER 2023)
FIGURE 18 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
FIGURE 19 LATENT TB TESTING MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 20 LATENT TB TESTING MARKET: ECOSYSTEM ANALYSIS
FIGURE 21 LATENT TB TESTING MARKET: PORTER'S FIVE FORCES ANALYSIS
FIGURE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF LATENT TB TESTS
FIGURE 23 KEY BUYING CRITERIA FOR LATENT TB TESTS
FIGURE 24 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
FIGURE 25 DEALS AND FUNDING IN LATENT TB TESTING MARKET
FIGURE 26 MARKET POTENTIAL OF AI TO ENHANCE R&D IN LATENT TB TESTING MARKET
FIGURE 27 NORTH AMERICA: LATENT TB TESTING MARKET SNAPSHOT
FIGURE 28 ASIA PACIFIC: LATENT TB TESTING MARKET SNAPSHOT
FIGURE 29 REVENUE ANALYSIS OF KEY PLAYERS IN LATENT TB TESTING MARKET (2021-2023)
FIGURE 30 MARKET SHARE ANALYSIS OF KEY PLAYERS IN LATENT TB TESTING MARKET (2023)
FIGURE 31 NORTH AMERICA: MARKET SHARE ANALYSIS OF KEY PLAYERS (2023)
FIGURE 32 EUROPE: MARKET SHARE ANALYSIS OF KEY PLAYERS (2023)
FIGURE 33 ASIA PACIFIC: MARKET SHARE ANALYSIS OF KEY PLAYERS (2023)
FIGURE 34 LATENT TB TESTING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
FIGURE 35 LATENT TB TESTING MARKET: COMPANY FOOTPRINT
FIGURE 36 LATENT TB TESTING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
FIGURE 37 EV/EBITDA OF KEY VENDORS
FIGURE 38 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 39 BRAND COMPARISON FOR IGRA
FIGURE 40 QIAGEN: COMPANY SNAPSHOT (2023)
FIGURE 41 REVVITY: COMPANY SNAPSHOT (2023)
FIGURE 42 BEIJING WANTAI BIOPHARMACEUTICAL: COMPANY SNAPSHOT (2023)
FIGURE 43 SANOFI: COMPANY SNAPSHOT (2023)
FIGURE 44 ENDO: COMPANY SNAPSHOT (2023)
FIGURE 45 BIOMERIEUX: COMPANY SNAPSHOT (2023)
FIGURE 46 SD BIOSENSOR: COMPANY SNAPSHOT (2023)